<DOC>
	<DOCNO>NCT01095393</DOCNO>
	<brief_summary>Observational registry ass longer-term risk serious infection malignancy report TNFα-blocker therapy , well longer-term risk cardiovascular thromboembolic event adult Rheumatoid Arthritis ( RA ) patient treat Cimzia® compare non-biologic DMARD-treated control .</brief_summary>
	<brief_title>National Data Bank Rheumatic Disease Registry Study Safety Patients With Rheumatoid Arthritis Treated With Cimzia® Disease-modifying Antirheumatic Drugs ( DMARDs )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>RA start treatment certolizumab pegol ( Cimzia® ; CZP ) nonbiologic DMARD within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>CZP</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>NDB</keyword>
	<keyword>registry</keyword>
</DOC>